Search filters

List of works by Christy Ralph

A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.

scientific article published on 10 September 2015

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer ⬇️

scientific article

Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era.

scientific article published on 3 December 2015

Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going? ⬇️

scientific article

Incidence of Post-ablation Syndrome Following Image-Guided Percutaneous Cryoablation of Renal Cell Carcinoma: A Prospective Study ⬇️

scientific article published on 28 November 2017

Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. ⬇️

scientific article published in January 2018

Metastatic castrate-resistant prostate cancer with a late, complete and durable response to docetaxel chemotherapy: a case report

scientific article

Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study ⬇️

scientific article published on 23 May 2017

Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma.

scientific article published on 23 February 2010

Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients.

scientific article published on 4 November 2015

Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy ⬇️

scientific article

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma ⬇️

scientific article

Talimogene laherparepvec in the treatment of melanoma

scientific article

Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells

scientific article published on 5 November 2010

Paulina is supported by:

About Paulina

Help